Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.
Sushil K BadrisingRebecca D LouhanepessyVincent van der NoortJacobien KiefferJules L L M CoenenPaul HambergAart BeekerNils WagenaarMarnix LamFiliz CelikOlaf J L LoosveldAd OostdijkHanneke ZuetenhorstJeantine M de FeijterVincent O DezentjéSuzan Ras-van SpijkErik VegtJohn B HaanenLonneke V van de Poll-FranseWilbert ZwartAndries M BergmanPublished in: Prostate cancer and prostatic diseases (2021)
In contemporary, extensively pretreated mCRPC patients, Ra-223 treatment induced complete pain responses while integrated analysis of HRQoL, pain response, and opioid use demonstrated that the majority of patients derive clinical benefit.
Keyphrases
- end stage renal disease
- chronic pain
- newly diagnosed
- ejection fraction
- neuropathic pain
- chronic kidney disease
- rheumatoid arthritis
- oxidative stress
- systemic lupus erythematosus
- patient reported outcomes
- high glucose
- systemic sclerosis
- endothelial cells
- anti inflammatory
- combination therapy
- ankylosing spondylitis
- postoperative pain